A non-coding cationic lipid DNA complex produces lasting anti-leukemic effects

References

• Gowen BB, Fairman J, Dow S, Troyer R, Wong MH, Jung KH, et al. Prophylaxis with cationic liposome-DNA complexes protects hamsters from phleboviral disease: importance of liposomal delivery and CpG motifs. Antiviral Res 2009; 81:37 - 46
   PubMedGoogle Scholar
• Yasuda K, Ogawa Y, Kishimoto M, Takagi T, Hashida M, Takakura Y. Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes, Biochem. Biochem Biophys Res Commun 2002; 293:344 - 348
   PubMed Web of Science ®Google Scholar
• Yasuda K, Ogawa Y, Yamane I, Nishikawa M, Takakura Y. Macrophage activation by a DNA/cationic liposome complex requires endosomal acidification and TLR9-dependent and -independent pathways. J Leukoc Biol 2005; 77:71 - 79
   PubMed Web of Science ®Google Scholar
• Yasuda K, Yu P, Kirschning CJ, Schlatter B, Schmitz F, Heit A, et al. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J Immunol 2005; 174:6129 - 6136
   PubMed Web of Science ®Google Scholar
• Zaks K, Jordan M, Guth A, Sellins K, Kedl R, Izzo A, et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006; 176:7335 - 7345
   PubMed Web of Science ®Google Scholar
• Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD, Potter TA. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. J Immunol 1999; 163:1552 - 1561
   PubMed Web of Science ®Google Scholar
• Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434:772 - 777
   PubMed Web of Science ®Google Scholar
• Charak BS, Brynes RK, Chagyoli M, Kortes V, Tefft M, Mazumder A. Graft versus leukemia effect after transplantation with IL-2 activated bone marrow. Correleation with erradication of residual disease. Transplantation 1993; 56:31
   PubMed Web of Science ®Google Scholar
• Butturini A, Gale RP. Graft versus leukemia in humans. Cancer Treat Res 1995; 76:299 - 314
   PubMedGoogle Scholar
• Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097 - 2100
   PubMed Web of Science ®Google Scholar
• Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93:2336 - 2341
   PubMed Web of Science ®Google Scholar
• Rufer N, Wolpert E, Helg C, Tiercy JM, Gratwohl A, Chapuis B, et al. HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation. Transplantation 1998; 66:910 - 916
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097 - 2100
   PubMed Web of Science ®Google Scholar
• Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for malignant disease. Hematology 2001; 375 - 391
   PubMedGoogle Scholar
• Claxton DF, Ehmann C, Rybka W, Claxton DF, Ehmann C, Rybka W. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2005; 130:256 - 264
   PubMed Web of Science ®Google Scholar
• Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999; 93:2336 - 2341
   PubMed Web of Science ®Google Scholar
• Rufer N, Wolpert E, Helg C, Tiercy JM, Gratwohl A, Chapuis B, et al. HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation. Transplantation 1998; 66:910 - 916
   PubMed Web of Science ®Google Scholar
• Choudhury A, Toubert A, Sutaria S, Charron D, Champlin RE, Claxton DF. Human leukemia-derived dendritic cells- ex vivo development of specific antileukemic cytotoxicity. Crit Rev Immunol 1998; 18:121 - 131
   PubMed Web of Science ®Google Scholar
• Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, et al. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1997; 89:1133 - 1142
   PubMed Web of Science ®Google Scholar
• Choudhury A, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999; 93:780 - 786
   PubMed Web of Science ®Google Scholar
• Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88:2450 - 2457
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N, et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90:2529 - 2534
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6:1018 - 1023
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Wang C, Champlin RE, Davis MM. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Can Res 1999; 59:2675 - 2681
   PubMed Web of Science ®Google Scholar
• Qazilbash MH, Wieder ED, Thall PF, Wang X, Rios RL, Lu S, et al. PR1 Peptide Vaccine-Induced Immune Response Is Associated with Better Event-Free Survival in Patients with Myeloid Leukemia. ASH Annual Meeting Abstracts 2007; 110:283
   Google Scholar
• Gaiger A, Reese V, Disis ML, Cheever MA, Gaiger A, Reese V, et al. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 2000; 96:1480 - 1489
   PubMed Web of Science ®Google Scholar
• Asemissen AM, Keilholz U, Tenzer S, Muller M, Walter S, Stevanovic S, et al. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res 2006; 12:7476 - 7482
   PubMed Web of Science ®Google Scholar
• Kamstock D, Guth A, Elmslie R, Kurzman I, Liggitt D, Coro L, et al. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther 2006; 13:306 - 317
   PubMed Web of Science ®Google Scholar
• Sahin MB, Perman SM, Jenkins G, Clark SS. Perillyl alcohol selectively induces G0/G1 arrest and apoptosis in Bcr/Abl-transformed myeloid cell lines. Leukemia 1999; 13:1581 - 1591
   PubMed Web of Science ®Google Scholar
• Ling X, Wang Y, Dietrich MF, reeff M, Arlinghaus RB. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice. Oncogene 2006; 25:4483 - 4490
   PubMed Web of Science ®Google Scholar
• Murphy WH, Urnovitz HB, Maryanski JL, Abrams GD. Characterization of transplantable myelomonocytic leukemia WEHI-3B in syngeneic BALB/c mice. Proc Soc Exp Biol Med 1978; 157:556 - 564
   PubMed Web of Science ®Google Scholar
• Fairman J, Moore J, Lemieux M, Van RK, Geng Y, Warner J, Abel K. Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study. Hum Vaccin 2008; 5
   Web of Science ®Google Scholar